Nature Publishing Group, publisher of Nature, and other science journals and reference works NATURE.COM NATURE NEWS NATUREJOBS NATUREEVENTS ABOUT NPG
Help Nature.com site index  
Leukemia
SEARCH     advanced search my account e-alerts subscribe register
Journal home
Advance online publication
Current issue
Archive
Press releases
For authors
For referees
Contact editorial office
About the journal
For librarians
Subscribe
Advertising
naturereprints
Contact NPG
Customer services
Site features
NPG Subject areas
Access material from all our publications in your subject area:
Biotechnology Biotechnology
Cancer Cancer
Chemistry Chemistry
Dentistry Dentistry
Development Development
Drug Discovery Drug Discovery
Earth Sciences Earth Sciences
Evolution & Ecology Evolution & Ecology
Genetics Genetics
Immunology Immunology
Materials Materials Science
Medical Research Medical Research
Microbiology Microbiology
Molecular Cell Biology Molecular Cell Biology
Neuroscience Neuroscience
Pharmacology Pharmacology
Physics Physics
Browse all publications
 
June 2002, Volume 16, Number 6, Pages 985-992
Table of contents    Previous  Abstract  Next   Full text  PDF
Spotlight on Chronic Lymphocytic Leukemia
Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia
P Dreger1 and E Montserrat2

1Department of Hematology, AK St Georg, Hamburg, Germany

2Institute of Hematology and Oncology, Hematology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain

Correspondence to: P Dreger, AK St Georg, Dept Hematology, Lohmühlenstr. 5, 20099 Hamburg, Germany; Fax: 49 40 2890 4226 or E Montserrat, Dept Hematology, Hospital Clinic, Villaroel 170, 08036 Barcelona, Spain; Fax: 34 93 227 5517

Abstract

Allogeneic and autologous stem cell transplantation (SCT) are increasingly considered for treatment of patients with chronic lymphocytic leukemia (CLL). In order to assess the potential therapeutic value of SCT for CLL, the present article aims at answering the following crucial questions: (1) Is SCT a curative treatment? (2) Does SCT improve the prognosis of poor-risk CLL? (3) Do risk factors exist which are useful for defining prognostic groups in terms of feasibility and post-transplant outcome? The efficacy of auto-SCT relies exclusively on the cytotoxic therapy administered. To date, there is only limited hope that autotransplantation can cure the disease. Nevertheless, the results of the published series suggest that auto-SCT is capable of improving the prognosis of CLL with poor-risk features. Well defined favorable conditions for successful autografting are the status of the disease (CR or VGPR) and the number of lines of therapy (<2) before transplantation. The crucial anti-leukemic principle of allo-SCT consists in the immune-mediated GVL effects conferred with the graft. The GVL activity explains that allografting seems to be curative for at least a subset of patients. However, as long as allo-SCT in CLL is still associated with an excessively high treatment-related mortality, only selected patients with advanced poor-risk disease should be considered for allografting. The development of conditioning regimens with reduced intensity may allow extending the indications of allogeneic SCT for CLL in the near future.

Leukemia (2002) 16, 985-992. DOI: 10.1038/sj/leu/2402530

Keywords

CLL; stem cell transplantation; review

Received 17 September 2001; accepted 16 January 2002
June 2002, Volume 16, Number 6, Pages 985-992
Table of contents    Previous  Abstract  Next   Full text  PDF
Privacy Policy © 2002 Nature Publishing Group